{"id":"W3087464965","doi":"10.1056/nejmoa2002788","title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1479,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Foundation Medicine; Pharmacyclics; Novartis Pharma; EMD Serono; Genentech; LEO Pharma; Bavarian Nordic; Ipsen; Janssen Pharmaceuticals; AstraZeneca Australia; Astellas Pharma; Eisai; Bayer HealthCare; GlaxoSmithKline; UroGen Pharma; Takeda Oncology; Mirati Therapeutics; University of Patras; Clovis Oncology; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Janssen Biotech; Les Laboratories Pierre Fabre; Massachusetts Medical Society; Advanced Accelerator Applications; Merck KGaA; Endocyte; Pfizer; Incyte; Progenics Pharmaceuticals; Genesis Pharma; Yale University; Exelixis; Sanofi; Amgen; Heron Therapeutics; EUSA Pharma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Avelumab; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Medicine; Internal medicine; Carcinoma; Standard of care; Immunotherapy; Cancer; Bladder cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006101752,0.0002644009,0.0008990797,0.0002201871,0.0001849771,0.0002360257,0.0003259037,0.0003156851,0.001473627],"category_scores_gemma":[0.0006417236,0.0001010314,0.0005148413,0.0001910793,0.000259224,0.0002024577,0.0001805088,0.0006807658,0.0001866754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004840873,"about_ca_system_score_gemma":0.0004253859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003449558,"about_ca_topic_score_gemma":0.0008453928,"domain_scores_codex":[0.9998293,0.00006777736,0.0000175909,0.00003366119,0.00002273514,0.00002889129],"domain_scores_gemma":[0.9996679,0.00008858102,0.0001032339,0.00002803633,0.00001397626,0.00009832592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3704406,0.01461194,0.02778429,0.001873429,0.001603408,0.0004648724,0.0002165214,0.00318978,0.07028157,0.0004828458,0.003228125,0.5058225],"study_design_scores_gemma":[0.2814087,0.5701862,0.1047413,0.0002954458,0.001521144,0.002287611,0.00006992011,0.004652376,0.02025409,0.0007596661,0.01377188,0.00005173948],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933205,0.005304705,0.0002710121,0.0001176523,0.00004437673,0.0002615705,0.00009482315,0.00002893454,0.0005565874],"genre_scores_gemma":[0.9968508,0.001749152,0.0005485074,0.0001454526,0.00006192078,0.0002119787,0.0001578871,0.000003320497,0.0002710266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001473627,"threshold_uncertainty_score":0.004929781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05678166625801688,"score_gpt":0.3231609399121029,"score_spread":0.266379273654086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}